Analysis of the fungal contamination in Cassia acutifolia Delile (sene) and Peumus boldus (Molina) Lyons (boldo-do-Chile) sold in Campinas, Brazil

A sociedade atual tem buscado a fitoterapia como um importante recurso terapêutico, sendo a avaliação da qualidade microbiológica destes produtos um requisito essencial, considerando a sua origem. Deste modo, o objetivo da pesquisa foi realizar a contagem e a identificação de fungos filamentosos em 20 amostras de folhas de Cassia acutifolia Delile (sene) e de Peumus boldus (Molina) Lyons (boldo-do-Chile) comercializadas em farmácias de manipulação e mercados da cidade de Campinas, Brasil, usando as técnicas microbiológicas clássicas. Os resultados obtidos evidenciaram que 45% das amostras analisadas se situavam fora dos padrões estabelecidos pela Organização Mundial da Saúde (OMS). Não foram observadas diferenças significativas na análise quantitativa da contaminação fúngica entre amostras comercializadas em farmácias de manipulação e mercados, tanto para o boldo-do-Chile como para a sene. Os fungos identificados nestas amostras foram: Aspergillus, Penicillium, Phoma, Cladosporium, Trichoderma, Rhizopus, Mucor, Aureobasidium pullulans, Mycelia sterilia, Acremonium e Monilia sitophila. Estes resultados demonstraram o baixo nível de qualidade desses fitoterápicos, pois, além do elevado número de amostras contaminadas, foram identificados fungos de gêneros produtores de micotoxinas, como o Aspergillus e o Penicillium. Verifica-se a urgência na realização de adequado controle de qualidade microbiológico dos fitoterápicos e de implantação de fiscalização efetiva, para garantir a segurança e eficácia destes produtos.The consumption of medicinal plants has increased during the last years. The purpose of this study was to evaluate and identify fungi specimens present in samples of Cassia acutifolia Delile (20) (sene) and Peumus boldus (Molina) Lyons (Boldo-do-Chile) (20), that were purchased in drugstores and markets of Campinas, Brazil, by usual methods. The results showed that 45% of samples did not fit the minimum quality standards recommended by the World Health Organization (WHO). No differences were observed in the quantitative analysis between the samples sold at the drugstores and at the markets. The identified genera and species of fungi were: Aspergillus, Penicillium, Phoma, Cladosporium, Trichoderma, Rhizopus, Mucor, Aureobasidium pullulans, Mycelia sterilia, Acremonium and Monilia sitophila. Considering the level of contamination and the presence of Aspergillus and Penicillium, which are able to produce mycotoxins, there is an urgent need for quality control of the phytotherapic products in order to assure their efficacy and safety

Beer industry in Brazil: Economic aspects, characteristics of the raw material and concerns

Barley is one of the most cultivated grains in the world with numbers rising every year due to market demand. In the past decade, Brazil has shown impressive numbers considering beer production. However, barley cultivation does not reach the necessary amount for the beer industry which raises the need to import barley or to use some alternatives, such as, adjuncts. The most common adjunct used is corn, which is considered a good source of carbohydrates, but also a very contaminated grain. Research and monitoring of all of the steps of the chain is being carried out to improve not only the malt quality but also the competitiveness in world market

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.Peer reviewe

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Fungi and mycotoxins in corn grains and their consequences

O milho é uma das culturas mais importantes no mundo, utilizada extensivamente para alimentação animal e consumo humano, no entanto, são susceptíveis à contaminação por micotoxinas. Esses compostos são produzidos por cepas toxigênicas de fungos e podem estar presentes no solo, na água, ou transportados pelo vento. A ocorrência e proliferação de fungos em grãos de milho pode ser estimulada por fatores como o maior teor de umidade nos grãos, maior temperatura e tempo de armazenamento que levam à redução na produtividade e qualidade, com perdas econômicas significativas. O problema não acaba perdas de produção, devido que as micotoxinas representam um risco potencial para a saúde humana e animal. Os limites máximos aceitáveis de micotoxinas variam muito entre países, e os produtores de grãos de milho, devem adotar as regulamentações estabelecidas do país originário e as legislações dos países de destino. Esta revisão foca na presença de micotoxinas em grãos ardidos, oriundos de espigas de milho doentes devido à presença de fungos, em especial, as produzidas pelos fungos Fusarium spp., Penicillium spp. e Aspergillus spp. Foi concluído que devido aos efeitos tóxicos das micotoxinas tem que ser realizados controles rigorosos tal como aplicação das práticas de manejo integradas, uso de novas tecnologias para detecção de contaminantes e utilização das recomendações feitas pelos produtores para garantir que os grãos de milho sejam seguros para o consumo104559570Corn is one of the most important crops in the world, used extensively for animal feed and human consumption, however, is susceptible to mycotoxin contamination. These compounds are produced by toxigenic strains of fungi and may be present in soil, water, or transported by the wind. The migration and proliferation of corn grains can be stimulated by factors such as the higher grain moisture content, higher temperature and storage time, leading to reduction in productivity and quality, with economic losses. The problem does not end production losses, since mycotoxins pose a potential risk to human and animal health. Acceptable maximum limits for mycotoxins vary widely between countries and maize grain producers must adopt the regulations established of the originating country and the laws of the destination countries. This review focuses on the presence of mycotoxins in rot grains from diseased corn cobs due to the presence of fungi, especially mycotoxins produced by the fungi Fusarium spp., Penicillium spp. and Aspergillus spp. It was concluded that due to the toxic effects of mycotoxins must be carried out rigorous controls such as the application of integrated management practices, use of new technologies for contaminant detection and the use of recommendations made by producers to ensure that maize grains are safe for consumptio

Pivovarský průmysl v Brazílii: Ekonomické aspekty, charakteristika surovin a rizika

Barley is one of the most cultivated grains in the world with numbers rising every year due to market demand. In the past decade, Brazil has shown impressive numbers considering beer production. However, barley cultivation does not reach the necessary amount for the beer industry which raises the need to import barley or to use some alternatives, such as, adjuncts. The most common adjunct used is corn, which is considered a good source of carbohydrates, but also a very contaminated grain. Research and monitoring of all of the steps of the chain is being carried out to improve not only the malt quality but also the competitiveness in world market646284286Ječmen je jednou z nejvíce pěstovaných obilovin na světě, po níž se každoročně zvyšuje poptávka na trhu. V uplynulém desetiletí vykazuje Brazílie působivá data, pokud jde o výrobu piva. Pěstování ječmene však nedosahuje potřebného množství pro výrobu piva, což vyvolává potřebu dovozu ječmene nebo využití některých alternativ, např. surogace. Nejběžnějším přídavkem je kukuřice, která je považována za dobrý zdroj sacharidů, ale je zde riziko kontaminace zrn. Výzkum a sledování všech kroků řetězce probíhá s cílem zlepšit nejen kvalitu sladu, ale také konkurenceschopnost na světovém trh

Fusarium mycotoxins in beer production: characteristics, toxicity, incidence, legislation, and control strategies

A cerveja é uma bebida alcoólica conhecida mundialmente devido a diversas razões sociais e econômicas e, portanto, o mercado cervejeiro está se expandindo cada vez mais. Com isso, aumentou-se a variedade de cervejas com características organolépticas variadas e diferentes composições através da utilização de adjuntos como trigo, arroz e milho, dentre outros. Entretanto, esses adjuntos são alvos de inúmeras micotoxinas. Dentre as micotoxinas produzidas pelo gênero Fusarium, destacam-se o desoxinivalenol, zearalenona e as fumonisinas, que proporcionam efeitos tóxicos para animais e humanos. Podem também ocasionar impacto significativo para a economia, uma vez que legislações são aplicadas para controle destas micotoxinas no produto final. Apesar dos limites para diversas micotoxinas serem estabelecidos para as matérias-primas envolvidas na produção de cerveja, até o momento, não existe legislação específica para os limites de micotoxinas em cerveja, sendo essencial a aplicação de medidas de controle para a presença das micotoxinas de Fusarium durante o processamento de cerveja112247256FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP2017/04811- 4Beer is a worldwide known alcoholic beverage due to many social and economic reasons and therefore the brewing market is expanding. Because of this, the variety of beers with varied organoleptic characteristics and different compositions was increased using different adjuncts like wheat, rice, corn, among others. However, these adjuncts are targets for numerous Fusarium mycotoxins - mainly deoxynivalenol, zearalenone and fumonisins, these may cause toxic effects to animals and humans. These toxins are also implicated in economic losses, due to worldwide regulations applied for unprocessed and processed food products. Currently, the limits for several mycotoxins have been established for the raw materials involved in brewing, however, there is no specific regulation for mycotoxin contamination in beer; therefore it is essential to apply control measures for the presence of Fusarium mycotoxins during the beer processin